CISPLATIN INJECTION 1 MG
CISPLATIN : 1 MG · DIN 02409186 · FRESENIUS KABI CANADA LTD
Health Canada status: APPROVED
What is CISPLATIN INJECTION?
CISPLATIN INJECTION 1 MG contains CISPLATIN : 1 MG. It is listed in the Health Canada Drug Product Database under DIN 02409186, held by FRESENIUS KABI CANADA LTD, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as approved, status dated 19-May-2015. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02409186 |
|---|---|
| Brand name | CISPLATIN INJECTION |
| Generic / active ingredient | CISPLATIN : 1 MG |
| Manufacturer | FRESENIUS KABI CANADA LTD |
| Strength | 1 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | L01XA01 CISPLATIN |
| AHFS class | 10:00.00 |
| Biosimilar | No |
| Health Canada status | APPROVED |
| Status date | 19-May-2015 |
What can be used instead?
Other Canadian products sharing ATC code L01XA01 CISPLATIN. 4 of 13 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CISPLATIN INJECTION | 1.0 MG | SOLUTION | TEVA CANADA LIMITED | MARKETED | DIN 02403188 |
| CISPLATIN INJECTION BP | 1 MG | SOLUTION | HIKMA CANADA LIMITED | MARKETED | DIN 02536285 |
| CISPLATIN INJECTION BP | 1 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02126613 |
| CISPLATIN INJECTION, BP | 1 MG | SOLUTION | ACCORD HEALTHCARE INC | MARKETED | DIN 02355183 |
| CISPLATIN INJ 0.5MG/ML | .5 MG | LIQUID | DAVID BULL LABORATORIES (PTY) LTD. | CANCELLED POST MARKET | DIN 00644293 |
| CISPLATIN INJ 1MG/ML | 1 MG | LIQUID | DAVID BULL LABORATORIES (PTY) LTD. | CANCELLED POST MARKET | DIN 00692743 |
| CISPLATIN INJECTION | 1 MG | SOLUTION | OMEGA LABORATORIES LIMITED | APPROVED | DIN 02422034 |
| CISPLATIN INJECTION | 1 MG | SOLUTION | STRIDES PHARMA CANADA INC | APPROVED | DIN 02393832 |
| CISPLATIN INJECTION BP | 1 MG | SOLUTION | SANDOZ CANADA INCORPORATED | CANCELLED POST MARKET | DIN 02366711 |
| CISPLATIN INJECTION, MYLAN STD. | 1 MG | SOLUTION | MYLAN PHARMACEUTICALS ULC | CANCELLED POST MARKET | DIN 02396890 |
Who else supplies CISPLATIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CISPLATIN appears in 37 registered pack listings across 7 markets, published on 5 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.